PL2769737T3 - Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases - Google Patents
Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseasesInfo
- Publication number
- PL2769737T3 PL2769737T3 PL14162613T PL14162613T PL2769737T3 PL 2769737 T3 PL2769737 T3 PL 2769737T3 PL 14162613 T PL14162613 T PL 14162613T PL 14162613 T PL14162613 T PL 14162613T PL 2769737 T3 PL2769737 T3 PL 2769737T3
- Authority
- PL
- Poland
- Prior art keywords
- etoposide
- combination
- proliferative diseases
- ctla4 antibody
- synergistic treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22691009P | 2009-07-20 | 2009-07-20 | |
| PCT/US2009/052209 WO2010014784A2 (en) | 2008-08-01 | 2009-07-30 | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| US12/462,168 US8119129B2 (en) | 2008-08-01 | 2009-07-30 | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| EP14162613.5A EP2769737B1 (en) | 2009-07-20 | 2009-10-29 | Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2769737T3 true PL2769737T3 (en) | 2017-08-31 |
Family
ID=43499324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14162613T PL2769737T3 (en) | 2009-07-20 | 2009-10-29 | Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases |
Country Status (17)
| Country | Link |
|---|---|
| EP (4) | EP2456790A1 (en) |
| JP (3) | JP5589077B2 (en) |
| KR (1) | KR101733255B1 (en) |
| CN (1) | CN102822200A (en) |
| AU (1) | AU2009350151B2 (en) |
| CY (1) | CY1119128T1 (en) |
| DK (1) | DK2769737T3 (en) |
| ES (2) | ES2768990T3 (en) |
| HR (1) | HRP20170785T1 (en) |
| HU (1) | HUE033312T2 (en) |
| LT (1) | LT2769737T (en) |
| MX (1) | MX2012000851A (en) |
| PL (1) | PL2769737T3 (en) |
| PT (1) | PT2769737T (en) |
| SI (1) | SI2769737T1 (en) |
| SM (1) | SMT201700293T1 (en) |
| WO (1) | WO2011011027A1 (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
| MX356367B (en) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function. |
| ES2699965T3 (en) * | 2011-03-10 | 2019-02-13 | Provectus Pharmatech Inc | A combination of rose bengal and anti-CTLA4 antibody for use in the treatment of cancer |
| US9717781B2 (en) * | 2011-08-08 | 2017-08-01 | Alexander Shneider | Methods and compositions relating to P62 for the treatment and prophylaxis of cancer |
| CN105025884B (en) * | 2013-03-01 | 2019-08-20 | 阿斯泰克斯制药公司 | drug combination |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| UA122479C2 (en) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Isolated ANTIBODY MOLECULE BINDS TO HUMAN PROGRAMMED DEATH-1 (PD-1) PROTEIN |
| PL3099717T3 (en) | 2014-01-31 | 2019-10-31 | Novartis Ag | Antibody molecules to tim-3 and uses thereof |
| EA201691765A1 (en) | 2014-03-14 | 2016-12-30 | Новартис Аг | ANTIBODY MOLECULES AGAINST LAG-3 AND THEIR APPLICATIONS |
| WO2015153820A1 (en) * | 2014-04-02 | 2015-10-08 | Felder Mitchell S | Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| KR20170066546A (en) * | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | Combination therapies |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| WO2016059602A2 (en) * | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| US10806787B2 (en) | 2015-02-16 | 2020-10-20 | Pharma Foods International Co., Ltd. | Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof |
| CN107531773A (en) * | 2015-03-11 | 2018-01-02 | 俄勒冈州普罗维登斯健康与服务部 | Compositions and methods for enhancing the effect of cancer therapy |
| DK3303394T3 (en) * | 2015-05-29 | 2020-07-06 | Agenus Inc | ANTI-CTLA-4 ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| HK1254404A1 (en) * | 2015-06-25 | 2019-07-19 | Advanced Accelerator Applications | Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors |
| CA2991805A1 (en) * | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| US11065332B2 (en) | 2015-11-04 | 2021-07-20 | Duke University | Combination therapy of immunotoxin and checkpoint inhibitor |
| CN108495651A (en) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | The antibody molecule and application thereof of anti-PD-1 |
| EP3693019A1 (en) | 2016-01-08 | 2020-08-12 | Taiho Pharmaceutical Co., Ltd. | Anti-tumor agent containing immunomodulator |
| CA3015241A1 (en) * | 2016-02-22 | 2017-08-31 | Onxeo | Combination therapies comprising immuno-oncology agents and belinostat |
| CN105560247B (en) * | 2016-03-04 | 2018-08-31 | 四川美大康华康药业有限公司 | A kind of Dasatinib composition tablet and preparation method thereof |
| EP3490561A4 (en) * | 2016-08-01 | 2020-04-08 | Ignyta, Inc. | COMBINATIONS FOR THE TREATMENT OF CANCER |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| SG11201907867TA (en) | 2017-02-28 | 2019-09-27 | Bristol Myers Squibb Co | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine |
| CN106943380B (en) * | 2017-05-17 | 2021-02-05 | 杜楠 | Application of VEGF monoclonal antibody and nano paclitaxel in preparation of medicine for treating cancerous abdominal adhesion |
| AU2018290749A1 (en) * | 2017-06-27 | 2019-12-12 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identifying and treating resistance to CTLA4 antagonists in leukemia |
| JP7365694B2 (en) * | 2017-06-29 | 2023-10-20 | 信夫 塚本 | Anti-tumor immunotherapy enhancer |
| CA3095134A1 (en) | 2018-03-28 | 2019-10-03 | Board Of Regents, The University Of Texas System | Identification of epigenetic alterations in dna isolated from exosomes |
| CN110960679A (en) * | 2018-09-28 | 2020-04-07 | 江苏康缘药业股份有限公司 | Anti-tumor pharmaceutical composition and application thereof |
| CN113412130A (en) * | 2018-12-08 | 2021-09-17 | 得克萨斯州大学系统董事会 | Identification and targeting of pro-tumor cancer-associated fibroblasts for diagnosis and treatment of cancer and other diseases |
| JP7859975B2 (en) | 2020-06-30 | 2026-05-15 | 塩野義製薬株式会社 | Combination therapy with anti-CCR8 antibodies and chemotherapy agents |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | Modifications of or for denatured antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| KR900005995A (en) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | Modified Interleukin-2 and Method of Making the Same |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| ATE145428T1 (en) | 1990-12-14 | 1996-12-15 | Cell Genesys Inc | CHIMERIC CHAINS FOR TRANSDUCTION OF RECEPTOR-CONNECTED SIGNALING PATHWAYS |
| US5120805A (en) | 1991-06-05 | 1992-06-09 | The Dow Chemical Company | Reactor with surface agitator for solution polymerization process |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| US5618829A (en) | 1993-01-28 | 1997-04-08 | Mitsubishi Chemical Corporation | Tyrosine kinase inhibitors and benzoylacrylamide derivatives |
| CA2167153A1 (en) | 1993-07-15 | 1995-01-26 | Caroline Joy Springer | Prodrugs of protein tyrosine kinase inhibitors |
| TW406020B (en) | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
| CZ25697A3 (en) | 1994-07-29 | 1997-09-17 | Smithkline Beecham Plc | Novel compounds |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5639757A (en) | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| EP0904278A4 (en) | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | Apoptosis inducing molecule ii |
| CN100503580C (en) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | Irreversible inhibitors of tyrosine kinases |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US6277381B1 (en) | 1997-03-21 | 2001-08-21 | Corixa Corporation | Compounds and methods for the diagnosis and treatment of Ehrlichia infection |
| EP0970128A1 (en) | 1997-03-21 | 2000-01-12 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
| EP1992633A1 (en) | 1997-11-03 | 2008-11-19 | Human Genome Sciences, Inc. | VEGI, an inhibitor of angiogenesis and tumor growth |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| ES2706547T3 (en) | 1998-12-23 | 2019-03-29 | Pfizer | Human monoclonal antibodies for CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| DE19956568A1 (en) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
| US6740665B1 (en) | 1999-02-10 | 2004-05-25 | Ramachandran Murali | Tyrosine kinase inhibitors and methods of using the same |
| EE04852B1 (en) | 1999-02-22 | 2007-06-15 | Gesellschaft Fuer Biotechnologische Forschung Mbh | C-21 Modified Epothiolones, Methods of Making and Using Them, and Use of a Pharmaceutical Composition in the Treatment of Cancerous or Other Proliferative Diseases |
| US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6329380B1 (en) | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
| WO2001000214A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| EP1206265B1 (en) | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| MXPA02002559A (en) | 1999-09-10 | 2002-07-30 | Merck & Co Inc | Tyrosine kinase inhibitors. |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE |
| AU778042B2 (en) | 1999-10-19 | 2004-11-11 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2001029025A2 (en) | 1999-10-19 | 2001-04-26 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| KR20080023768A (en) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | RNA sequence specific mediator of RNA interference |
| CN100523215C (en) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | Small RNA molecules mediating RNA interference |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| ATE316088T1 (en) | 2001-06-22 | 2006-02-15 | Merck & Co Inc | TYROSINE KINASE INHIBITORS |
| US6958340B2 (en) | 2001-08-01 | 2005-10-25 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003020276A1 (en) | 2001-08-30 | 2003-03-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| NZ536420A (en) * | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| AU2003259717A1 (en) | 2002-08-07 | 2004-02-25 | Bristol-Myers Squibb Company | Modulators of rabggt and methods of use thereof |
| KR100944575B1 (en) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Human monoclonal antibodies against CD20 |
| US7465446B2 (en) * | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
| US20050051208A1 (en) | 2003-06-17 | 2005-03-10 | Mount Robert L. | System for transferring heat in a thermoelectric generator system |
| US20050009891A1 (en) * | 2003-07-09 | 2005-01-13 | Lee Francis Y. | Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| KR100845354B1 (en) * | 2004-03-26 | 2008-07-09 | 화이자 프로덕츠 인코포레이티드 | Use of anti-CTLA-4 antibody |
| AU2005300315A1 (en) * | 2004-11-04 | 2006-05-11 | Pfizer Products Inc. | CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
| CA2602316A1 (en) * | 2005-03-23 | 2006-09-28 | Pfizer Products Inc. | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
| US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
| WO2007008463A2 (en) * | 2005-07-07 | 2007-01-18 | Coley Pharmaceutical Group, Inc. | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
| NZ568016A (en) | 2005-12-07 | 2011-12-22 | Medarex Inc | CTLA-4 antibody dosage escalation regimens |
| WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| JP2008066402A (en) | 2006-09-05 | 2008-03-21 | Fujifilm Corp | Imaging device and imaging apparatus |
| JP5618549B2 (en) * | 2007-03-15 | 2014-11-05 | ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド | Method of treatment using EGFR antibody and SRC inhibitor and related preparation |
| US8449886B2 (en) * | 2008-01-08 | 2013-05-28 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| WO2010014784A2 (en) * | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
-
2009
- 2009-10-29 PT PT141626135T patent/PT2769737T/en unknown
- 2009-10-29 CN CN2009801615246A patent/CN102822200A/en active Pending
- 2009-10-29 MX MX2012000851A patent/MX2012000851A/en active IP Right Grant
- 2009-10-29 EP EP09749268.0A patent/EP2456790A1/en not_active Withdrawn
- 2009-10-29 AU AU2009350151A patent/AU2009350151B2/en active Active
- 2009-10-29 SI SI200931652A patent/SI2769737T1/en unknown
- 2009-10-29 ES ES15166232T patent/ES2768990T3/en active Active
- 2009-10-29 LT LTEP14162613.5T patent/LT2769737T/en unknown
- 2009-10-29 SM SM20170293T patent/SMT201700293T1/en unknown
- 2009-10-29 WO PCT/US2009/062519 patent/WO2011011027A1/en not_active Ceased
- 2009-10-29 DK DK14162613.5T patent/DK2769737T3/en active
- 2009-10-29 PL PL14162613T patent/PL2769737T3/en unknown
- 2009-10-29 HU HUE14162613A patent/HUE033312T2/en unknown
- 2009-10-29 EP EP19207926.7A patent/EP3659596A1/en not_active Withdrawn
- 2009-10-29 KR KR1020127001497A patent/KR101733255B1/en active Active
- 2009-10-29 EP EP14162613.5A patent/EP2769737B1/en active Active
- 2009-10-29 ES ES14162613.5T patent/ES2629167T3/en active Active
- 2009-10-29 EP EP15166232.7A patent/EP2947098B1/en active Active
- 2009-10-29 JP JP2012521608A patent/JP5589077B2/en active Active
-
2014
- 2014-06-17 JP JP2014123960A patent/JP5957036B2/en active Active
- 2014-07-28 JP JP2014153222A patent/JP5957043B2/en active Active
-
2017
- 2017-05-26 HR HRP20170785TT patent/HRP20170785T1/en unknown
- 2017-06-29 CY CY20171100694T patent/CY1119128T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5589077B2 (en) | 2014-09-10 |
| JP2014167029A (en) | 2014-09-11 |
| EP2456790A1 (en) | 2012-05-30 |
| EP2769737A1 (en) | 2014-08-27 |
| ES2768990T3 (en) | 2020-06-24 |
| JP2012533619A (en) | 2012-12-27 |
| CN102822200A (en) | 2012-12-12 |
| AU2009350151A1 (en) | 2012-02-09 |
| CY1119128T1 (en) | 2018-02-14 |
| JP2014198737A (en) | 2014-10-23 |
| EP3659596A1 (en) | 2020-06-03 |
| HRP20170785T1 (en) | 2017-08-11 |
| AU2009350151B2 (en) | 2015-07-16 |
| HUE033312T2 (en) | 2017-11-28 |
| SI2769737T1 (en) | 2017-06-30 |
| EP2769737B1 (en) | 2017-04-05 |
| KR20120048564A (en) | 2012-05-15 |
| PT2769737T (en) | 2017-06-29 |
| DK2769737T3 (en) | 2017-07-24 |
| KR101733255B1 (en) | 2017-05-08 |
| SMT201700293T1 (en) | 2017-07-18 |
| EP2947098A1 (en) | 2015-11-25 |
| JP5957043B2 (en) | 2016-07-27 |
| LT2769737T (en) | 2017-06-26 |
| JP5957036B2 (en) | 2016-07-27 |
| ES2629167T3 (en) | 2017-08-07 |
| MX2012000851A (en) | 2012-06-08 |
| EP2947098B1 (en) | 2019-11-20 |
| WO2011011027A1 (en) | 2011-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2769737T1 (en) | Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases | |
| ZA200906210B (en) | 3-Imidazolyl-Indoles for the treatment of proliferative diseases | |
| IL244197A0 (en) | Anti-cd100 antibodies and methods for using the same | |
| HUE047994T2 (en) | Bardoxolone methyl for the treatment of obesity | |
| LT3023438T (en) | Anti-gitr antibodies | |
| IL216509A0 (en) | Use of an anti-tau ps422 antibody for the treatment of brain diseases | |
| PL2520259T3 (en) | Diaper | |
| ZA201208172B (en) | Methods for the treatment of il-1b related conditions | |
| EP2627242A4 (en) | Method and device for examining the surface temperature of a body part | |
| BR112012004836A2 (en) | pyrazinylpyridines useful for the treatment of proliferative diseases | |
| IL223290A (en) | Anti il-1α antibodies for the treatment of arthritis | |
| ZA201202793B (en) | Humanized antibodies against human il-22ra | |
| IL213761A0 (en) | Novel ortho-aminoamides for the treatment of cancer | |
| GB0905972D0 (en) | Antibodies against IL-17BR | |
| ZA201300858B (en) | Testosterone solutions for the treatment of testosterone deficiency | |
| IL216491A0 (en) | Combination therapy for the treatment of multiple myeloma | |
| WO2010083208A9 (en) | Treating neuropsychiatric diseases | |
| PL2608685T3 (en) | Device for the treatment of tobacco | |
| ZA201302639B (en) | Antibodies for the treatment of hiv | |
| PT2593423E (en) | Process for the preparation of contrast agents | |
| GB0902916D0 (en) | Antibody therapy | |
| EP2780766A4 (en) | Devices for quantifying the passage of time | |
| AU2009905505A0 (en) | The Treatment of Urine | |
| GB0907900D0 (en) | Radar apparatus with amplifier duplexer | |
| PL392838A1 (en) | Device for lifting the rear edge of the engine bonnet |